Nyxoah (NYXH) has released an update.
Nyxoah, a medical tech company focused on innovative treatments for Obstructive Sleep Apnea, announced raising $27 million through its At-the-Market offering, selling 3 million shares to a U.S. healthcare investor. The injection of funds is aimed at reinforcing the company’s U.S. market presence and supporting the upcoming launch of its Genio system in the States. This financial move follows the company’s successful European CE Mark and positive study outcomes, positioning Nyxoah for potential FDA approval and U.S. commercialization.
For further insights into NYXH stock, check out TipRanks’ Stock Analysis page.
